What does the abbreviation Zosyn (piperacillin/tazobactam) stand for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Zosyn Abbreviation and Brand Name

Zosyn is the brand name (not an abbreviation) for the combination antibiotic piperacillin/tazobactam, marketed as Tazocin in some international markets. 1

Understanding the Nomenclature

  • Zosyn is the proprietary brand name used in the United States for the fixed-dose combination of piperacillin (a broad-spectrum ureidopenicillin) and tazobactam (a beta-lactamase inhibitor) 1, 2

  • Tazocin is the alternative brand name used in European and other international markets for the identical piperacillin/tazobactam formulation 1, 3

  • The generic name is piperacillin/tazobactam, typically formulated in an 8:1 dose ratio (e.g., 4g piperacillin with 0.5g tazobactam) 4, 2

Clinical Significance of the Combination

  • Tazobactam functions as a beta-lactamase inhibitor that restores piperacillin's activity against beta-lactamase-producing bacteria, including Richmond and Sykes types II, III, IV, and V beta-lactamases, staphylococcal penicillinase, and some extended-spectrum beta-lactamases 2

  • The combination provides broad-spectrum coverage against gram-positive and gram-negative aerobic and anaerobic bacteria, making it suitable for polymicrobial infections 5

  • Zosyn/Tazocin is recommended in multiple international guidelines for moderate-to-severe infections including intra-abdominal infections, febrile neutropenia, and healthcare-associated infections 6

Common Clinical Usage Context

  • The drug is frequently abbreviated in clinical practice as "pip/tazo" or "PTZ" in medical documentation, though these are informal abbreviations rather than official designations 7

  • Zosyn was approved by the US FDA in 1993 and underwent reformulation in 2005 to improve stability and expand compatibility with other medications 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.